Zimmer Biomet

Q3 2026
Speakers

Nov 4, 2026 · 61 min

SECTION UNKNOWN · Q&A BOUNDARY NOT IDENTIFIEDKeys: / search · Space play · ←→ ±10s · [] sections

Transcript

Speaker 0

Unverified voice label

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2026 Earnings Conference Call. If anyone needs assistance at any time during the conference, please press the star followed by the zero. As a reminder, this conference is being recorded today, November 4th, 2026. Following today's presentation, there will be a question and answer session. At this time, all participants are in a listen-only mode.

If you have a question, please press the star followed by the one on your push button phone. I would now like to turn the conference over to David DiMartino, Senior Vice President, Investor Relations. Please go ahead.

Passages & reports (2)
  • Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2026 Ea…
  • will be a question and answer session. At this time, all participants are in a listen-only…

Speaker 1

Unverified voice label

Thank you, Operator, and good morning, everyone. Welcome to Zoom or Bimat's third quarter 2026 Earnings Conference Call. Joining on today's call are Von Tornos, our Chairman, President, and CEO, and Paul Stellato, our interim CFO and VP controller and chief accounting officer. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties.

For a detailed discussion of all these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements, please refer to our SEC filings. Please note
we assume no obligation to update these forward-looking statements, even if actual results or future expectations change materially. Additionally, the discussions on this call will include certain non-gap financial measures, some of which are proteling non-gap financial measures.

Reconciliation on these measures to the most directly comparable gap financial measures,
?and an explanation on our basis for calculating these measures ?is included within our third quarter's release, ?which can be found on our website, same environment.com. With that, I'll turn the call over Avon. Thank you, ?David. Good morning,

Passages & reports (11)
  • Thank you, Operator, and good morning, everyone. Welcome to Zoom or Bimat's third quarter …
  • during this call will include forward-looking statements. Actual results may differ materi…
  • we assume no obligation to update these forward-looking statements, even if actual results…
  • and
  • an explanation on our basis for calculating these measures
  • is
  • included within our third quarter's release,
  • which
  • can be found on our website, same environment.com. With that, I'll turn the call over Avon…
  • David. Good
  • morning,

Speaker 2

Unverified voice label

everyone. I'm thank you for joining today's call. I would like to start, as I always do, by thanking the more than 17,000 global Zimmer Biomed team members for your commitment, your resilience, and most importantly, your dedication to serving our customers and their patients each and every ?day. I'm grateful to work alongside you and I'm proud of the noble work we do to alleviate pain and improve the quality of life for people around the world.

Roughly six months from now, we will be celebrating our 100-year anniversary as a company.
?And as I often tell all of ?you, we are just getting started. Our boldest chapter remains ahead. During my prepared remarks this morning, I'll cover three things. First, ?I'll review our third quarter performance. Second, I'll discuss our increase outlook for 2026. And third, I'll provide an update on our three strategic priorities, which remain the same: people and culture, operational excellence, and

Passages & reports (9)
  • everyone. I'm thank you for joining today's call. I would like to start, as I always do, b…
  • day.
  • I'm grateful to work alongside you and I'm proud of the noble work we do to alleviate pain…
  • And
  • as I often tell all of
  • you,
  • we are just getting started. Our boldest chapter remains ahead. During my prepared remarks…
  • I'll
  • review our third quarter performance. Second, I'll discuss our increase outlook for 2026. …

Speaker 2

To begin, we delivered total net sales of 2 billion 63 million, resulting in 3.1% reported growth and 3.7% constant currency growth in the quarter compared to the third quarter of 2025, excluding the negative impact of China distributor network consolidation strategy, a one-time headwind in fiscal year 2026, our constant currency growth in the quarter will have been 4.7%. Notably, in the period, two-thirds of our bulk of business grew at least after single-digit or double-digit rates, validating the strength of our innovation cycle, the improvement in our commercial execution efforts, and the resilience of our global market environment.

In addition, these results are a testament to our efforts to diversify our portfolio over the last six
years as we continue to shift from a primarily joint reconstruction company to a broadly diversified business with leading platforms across SET, technology, and higher growth segments within core orthopedics. ?We are very proud of these quarter results as our HIPS and SET businesses grew upper single digits and technology and data, bone cement, and surgical grew in the teens, driven by 20% growth in robotics, data, and AI solutions.

Furthermore, we are
thrilled with the performance of a Paragon 28 acquisition, which continues to grow at roughly three times the food and ankle market, approaching 20% growth, which we do believe is sustainable. Altogether, this broad-based performance more than offset the expected challenges ?in our new business and China. Turning to our product categories and starting with hips, our global HIPAA business grew 7% on a constant currency basis in the third quarter, with growth of 5.8% in the US and 8.2% internationally.

US HIP growth continues to be driven by our new product, Cycle Strength, which includes Z1 or Triple Taper HIPAA stem, which now represents over 50% of all US hip stems, up from about 40% in the second
quarter of this year. HEMER, or Surgical Impactor, which is now being used in nearly 30% of all US primary hip cases, is also a major catalyst.

And third, orthogrid, which delivers its strongest quarter to date, with over two thirds of
cells coming from recurring revenue. OrthoGrid is a clear differentiator for Zimmer Biomed, and we look forward to its global expansion. Outside the US, we continue to build momentum with our Iodine coded HIPSTEM ?and CAP in Japan. This launch has far exceeded our high expectations, and we are rapidly increasing supply ?to meet the greater than expected demand from both existing customers ?and the new accounts that we're opening.

In addition, we're working on launch plans for other geographies outside of Japan. Turning to NIFS, as anticipated, the knee business continued to face headwinds during the quarter, with sales declining 2.6% on a constant currency
basis, including decreases of 2% in the US and 3.4% internationally. ?The US results reflect the non-impact of our Salesforce transition and a highly competitive knee implant market, while international NES continue to face pressure most significantly from China headwinds, without which global NEES will have been flat year over year this last third quarter.

While we continue to expect ongoing pressure in the near term in our knee business, we are confident in our strategy and plan to return to sustainable growth over the long term by number one, improving commercial execution. It's important to know that the US Salesforce
transition is nearing the halfway mark, and we started to see pockets of meaningful improvement across a variety of US territories.

Second, expanding our suite of robotics and enabling technology to meet the diverse needs of a wide array of surgeons around the world.

Passages & reports (23)
  • To begin, we delivered total net sales of 2 billion 63 million, resulting in 3.1% reported…
  • China distributor network consolidation strategy, a one-time headwind in fiscal year 2026,…
  • single-digit or double-digit rates, validating the strength of our innovation cycle, the i…
  • years as we continue to shift from a primarily joint reconstruction company to a broadly d…
  • We
  • are very proud of these quarter results as our HIPS and SET businesses grew upper single d…
  • thrilled with the performance of a Paragon 28 acquisition, which continues to grow at roug…
  • in
  • our new business and China. Turning to our product categories and starting with hips, our …
  • internationally. US HIP growth continues to be driven by our new product, Cycle Strength, …
  • quarter of this year. HEMER, or Surgical Impactor, which is now being used in nearly 30% o…
  • cells coming from recurring revenue. OrthoGrid is a clear differentiator for Zimmer Biomed…
  • and
  • CAP in Japan. This launch has far exceeded our high expectations, and we are rapidly incre…
  • to
  • meet the greater than expected demand from both existing customers
  • and
  • the new accounts that we're opening. In addition, we're working on launch plans for other …
  • basis, including decreases of 2% in the US and 3.4% internationally.
  • The
  • US results reflect the non-impact of our Salesforce transition and a highly competitive kn…
  • third quarter. While we continue to expect ongoing pressure in the near term in our knee b…
  • transition is nearing the halfway mark, and we started to see pockets of meaningful improv…

We recently announced a multi-year limited distribution and supply agreement with ThinkSurgical to distribute an exclusive version of the only wireless handheld T Mini miniature robotic system compatible with Persona knee. Most excitingly, we expect to file Monogram's 510K application with the FDA very soon, which is significantly ahead of schedule. We now anticipate that we can launch a surgeon guided, fully autonomous version of monogram in the first half of twenty twenty seven as opposed to the original expectation of a twenty twenty eight launch. ?

We
truly believe that this technology will represent a dramatic leap forward for the future of orthopedic care. We will be bringing monogram to the American Association of Hip and Knee Surgeons annual meeting later this week in Dallas to obtain additional feedback on the systems workflow from surgeons, or plan to have at least 225 robotic sales specialists, also remains very much on track.

Lastly, from a global standpoint, the China related headwinds will anniversary in January of 2027,
giving us visibility into improved global knee performance. SET accelerated to 7.1% growth on a constant currency basis in the quarter, including mid-single digit growth in the US. We continue to see strengths across our key franchises, including foot and ankle, sports medicine, CMFT, cranial, maxillofacial, thoracic, and upper extremities, all of which grew between mid-single digits and high teens in the period.

Critically, Paragon 28 cells grew over 18%, demonstrating the
successful integration of the business and representing a blueprint for future acquisitions. These results were partially offset by continued pressure in trauma and restorative therapies, both of which declined in the quarter as expected. Technology and data, bone cement and surgical grew 13% on a constant currency basis in the third quarter, once again led by the strong demand for a robotic offerings, including ROSA with Optimize and T-Mini.

Technology and data sales increase over 30% in the US, which
validation strategy of offering a comprehensive suite of customer-centric solutions to surgeons. Turning now to our updated outlook for the remain of 2026, with three solid quarters behind and an organic constant currency growth rate of 3.5% year to date, we are once again increasing our full year outlook. We are now raising our organic constant currency sales growth guidance to a range of three percent to three and a half percent from two and a quarter to three and a quarter, and raising also our adjusted earnings per share guidance to eight dollars and fifty cents to eight dollars and sixty cents from the previous guidance of eight dollars.

to $8.59. This increased
outlook captures our expectations for consistent global market dynamics, ongoing risk of US Salesforce disruption, China-related headwinds to the tune of nearly 100 basis points in the fourth quarter, and roughly 50 basis points for the full year 2026, as well as continue pressuring NIS. With that, let's turn to our three strategic priorities: people and culture, operational excellence, and innovation and diversification.

First, people and culture. We
continue to make steady progress as we transition to a fully dedicated and specialized Salesforce in the US. We started this initiative in earnest earlier this year, and I'm happy to share that three quarters into an eighth-quarter journey, we are proceeding ahead of our expectations with over 75% ?of our US Salesforce now being fully dedicated. While we are seeing some disruption associated with this transition, particularly in our new franchise, overall it has been less disruptive than we initially anticipated. ?

As
part of this strategy, we continue to add sales reps across key growth franchises such as Appet Extremities, Sports Medicine, CMFT, Robotics, and Furananco. We're going to continue to invest back into the business to support a smooth transition. ?And we're going to manage this project with the rigor that it requires. One key data point that reinforces our confidence in the pace and success of this transition is the sales rep turnover rates, which remain at healthy single digit levels.

Moving on to our
second priority, operational excellence. Over the last several years, we have improved manufacturing efficiency through SKU rationalization, technology advancements, and better planning. With demand continuing to grow, we are reshaping our US manufacturing network to make it more nimble and efficient. This effort includes closing select and underutilized manufacturing sites and consolidating operations into several facilities in Warsaw, Indiana, home to our global headquarters.

We're also reinvesting in our Warsaw facilities, bringing in more
advanced manufacturing processes. Together, these actions reflect our continued commitment to both Warsaw and US manufacturing. At the same time, we continue to consolidate our international manufacturing footprint into lower cost geographies while working with third party experts to thoughtfully implement artificial intelligence capabilities. ?All of these initiatives are designed to address and improve our operating expense cost base, which at 46% OPEX to sales leaves room for dramatic improvement.

We expect these strategies will improve flexibility, help us meet growing demand more
efficiently, and provide a long-term margin tailwind as the work progresses.

Passages & reports (30)
  • We recently announced a multi-year limited distribution and supply agreement with ThinkSur…
  • to file Monogram's 510K application with the FDA very soon, which is significantly ahead o…
  • original expectation of a twenty twenty eight launch.
  • We
  • truly believe that this technology will represent a dramatic leap forward for the future o…
  • on the systems workflow from surgeons, or plan to have at least 225 robotic sales speciali…
  • giving us visibility into improved global knee performance. SET accelerated to 7.1% growth…
  • foot and ankle, sports medicine, CMFT, cranial, maxillofacial, thoracic, and upper extremi…
  • successful integration of the business and representing a blueprint for future acquisition…
  • surgical grew 13% on a constant currency basis in the third quarter, once again led by the…
  • validation strategy of offering a comprehensive suite of customer-centric solutions to sur…
  • of 3.5% year to date, we are once again increasing our full year outlook. We are now raisi…
  • and raising also our adjusted earnings per share guidance to eight dollars and fifty cents…
  • outlook captures our expectations for consistent global market dynamics, ongoing risk of U…
  • for the full year 2026, as well as continue pressuring NIS. With that, let's turn to our t…
  • continue to make steady progress as we transition to a fully dedicated and specialized Sal…
  • expectations with over 75%
  • of
  • our US Salesforce now being fully dedicated. While we are seeing some disruption associate…
  • As
  • part of this strategy, we continue to add sales reps across key growth franchises such as …
  • And
  • we're going to manage this project with the rigor that it requires. One key data point tha…
  • second priority, operational excellence. Over the last several years, we have improved man…
  • more nimble and efficient. This effort includes closing select and underutilized manufactu…
  • advanced manufacturing processes. Together, these actions reflect our continued commitment…
  • experts to thoughtfully implement artificial intelligence capabilities.
  • All
  • of these initiatives are designed to address and improve our operating expense cost base, …
  • efficiently, and provide a long-term margin tailwind as the work progresses.

Speaker 2

We remain committed to investing both organically and inorganically to diversify our portfolio and increase our exposure to faster growing markets. As part of this strategy, we have launched a strategic venture platform focused on identifying and investing in early stage technologies with the potential to redefine the standard of care. Beyond capital, we will leverage Zimmer Biomeds strong capabilities across RD, clinical, regulatory, and commercialization to help accelerate the development and adoption of these exciting innovations.

By expanding access to
breakthrough technologies, this strategy reinforces our strong commitment to alleviating pain and improving the quality of life for people around the world. While early in the process, we are already evaluating several differentiated technologies to invest in and expect the number to grow in quarters to ?come. We genuinely believe that the combination of organic innovation programs, the advancement of this new venture platform, plus the work in our partnership with Deerfield Management and HSS, a $300 million investment commitment over eight years ?will accelerate our WEMGAR weighted average market growth rates towards an aspiration of 6%

Passages & reports (8)
  • We remain committed to investing both organically and inorganically to diversify our portf…
  • potential to redefine the standard of care. Beyond capital, we will leverage Zimmer Biomed…
  • breakthrough technologies, this strategy reinforces our strong commitment to alleviating p…
  • number to grow in quarters to
  • come.
  • We genuinely believe that the combination of organic innovation programs, the advancement …
  • will
  • accelerate our WEMGAR weighted average market growth rates towards an aspiration of 6%

Speaker unclear

?by

Passages & reports (1)
  • by

Speaker 2

the end of the decade. Beyond these endeavors, we remain committed to responsible MA to accelerate all diversification efforts pursuing deals that can replicate the strong success of our Paragon 28 acquisition. In summary, our results reflect the strength of a diversified global business with two-thirds of the portfolio growing at upper single-digit or double-digit rates, as evidenced by strong results in HIPS, SET, and technology and data. ?

We
are highly encouraged by the progress that we are making as an organization, while we also understand that there is still room to improve.

Passages & reports (4)
  • the end of the decade. Beyond these endeavors, we remain committed to responsible MA to ac…
  • reflect the strength of a diversified global business with two-thirds of the portfolio gro…
  • We
  • are highly encouraged by the progress that we are making as an organization, while we also…

Speaker 2

and entering twenty twenty seven from a position of strength with the objective of delivering accelerated performance, leveraging the great transformational work that we have done in 2026. With that, I'll turn the call over to Paul. Thank

Passages & reports (1)
  • and entering twenty twenty seven from a position of strength with the objective of deliver…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Thank you and good morning, everyone. As Yvonne discussed, third

Passages & reports (1)
  • Thank you and good morning, everyone. As Yvonne discussed, third

Speaker unclear

?quarter

Passages & reports (1)
  • quarter

Speaker 3

Unverified voice label

sales grew three point seven percent on a constant currency basis, driven by continued strength in hips, SET, and data and technology, bone cement and surgical, partially offset by the expected challenges and knees. ?We reported gap diluted earnings per share of $1 compared to gap diluted earnings per share of $1.16 in the third quarter of 2025. Higher revenue and a lower share count were offset by an increase in SGA associated with our Salesforce transformation, earnout adjustments from prior year acquisitions, and a modest step up in manufacturing costs.

Our adjusted earnings per share for the third quarter was $1.90, flat with the prior year quarter, as higher revenue and a lower share count were offset by the investments in the U.S. commercial organization and expected higher manufacturing costs. Pricing was a 70-basis
point headwind in the quarter, within our guidance range of up to 100 basis points of pricing pressure for the year.

Adjusted gross margin was 71.7%, a 90 basis point decrease from the prior year quarter and slightly ahead of our expectations.
?The year over year decline was primarily related to higher manufacturing costs, which were partially offset by a product mixed benefit. Adjusted operating margin was twenty-five point one percent, down one hundred and forty basis points year over year, reflecting our continued investment in the U.S.

commercial organization as we execute our Salesforce
transformation. Adjusted net interest and non operating expenses were seventy seven million dollars, a modest step up from the prior year, primarily due to currency fluctuations. Our adjusted effective tax rate was 17.6%, and fully diluted shares outstanding were $191.4 million, down year over year due to $500 million in share repurchases in the first half of 2026 and an additional $79 million during the third quarter. ?

Now
turning the cash in liquidity. ?The third quarter marked another strong quarter of cash generation with operating cash flow of $560 million and free cash flow of $372 million, both up about 34% on a year over year basis. We ended the quarter with approximately $400 million in cash and cash equivalents. Turning to our outlook for 2026, as Yvonne mentioned, we are raising our organic constant currency sales growth expectation to 3% to 3.5%, up from our prior range of 2.25% to 3.25%.

Given changes in currency rates, we now expect foreign exchange to be an approximate
25 basis point tailwind to full year revenue growth, down 25 basis points from our prior expectation, and we continue to anticipate Paragon 28 to contribute 110 basis points to full year reported sales growth. Given this, we now expect 2026 reported sales growth to be 4.4% to 4.9%, up from 3.9% to 4.9%.

Passages & reports (16)
  • sales grew three point seven percent on a constant currency basis, driven by continued str…
  • We
  • reported gap diluted earnings per share of $1 compared to gap diluted earnings per share o…
  • up in manufacturing costs. Our adjusted earnings per share for the third quarter was $1.90…
  • point headwind in the quarter, within our guidance range of up to 100 basis points of pric…
  • The
  • year over year decline was primarily related to higher manufacturing costs, which were par…
  • transformation. Adjusted net interest and non operating expenses were seventy seven millio…
  • $500 million in share repurchases in the first half of 2026 and an additional $79 million …
  • Now
  • turning the cash in liquidity.
  • The
  • third quarter marked another strong quarter of cash generation with operating cash flow of…
  • Turning to our outlook for 2026, as Yvonne mentioned, we are raising our organic constant …
  • 25 basis point tailwind to full year revenue growth, down 25 basis points from our prior e…
  • to 4.9%, up from 3.9% to 4.9%.

Shifting to the PL. For the full year, we now expect adjusted gross margin to be around 72%, 100 basis points higher than our prior expectation, driven by manufacturing efficiency initiatives and favorable product mix. ?We anticipate adjusted operating margin to decline a little more than 50 basis points year over year, consistent with our prior commentary, which reflects continued investments in our U.S. commercial organization.

We now expect full-year net interest and other non-operating expenses to be $300 million, modestly higher than our previous expectation
of $295 million, and continue to anticipate a full-year adjusted tax rate of approximately 18%. In addition, we remain on track to complete approximately $1 billion of share repurchases during the year, and we still expect around $193 million fully diluted weighted average shares outstanding for 2026.

Taken together, these factors support another increase in our adjusted EPS outlook. We now expect adjusted earnings per share of $8.50 to $8.60 for the year, up from $8.47 to $8.59, which
contemplates continued investment in our commercial organization, and we continue to anticipate free cash flow to grow 9% to 11% for the ?year. We remain focused on executing our strategy, delivering on our commitments, and positioning the company for sustainable long-term growth.

With that, I'll turn the call back over to David.

Passages & reports (8)
  • Shifting to the PL. For the full year, we now expect adjusted gross margin to be around 72…
  • We
  • anticipate adjusted operating margin to decline a little more than 50 basis points year ov…
  • of $295 million, and continue to anticipate a full-year adjusted tax rate of approximately…
  • outstanding for 2026. Taken together, these factors support another increase in our adjust…
  • contemplates continued investment in our commercial organization, and we continue to antic…
  • year. We
  • remain focused on executing our strategy, delivering on our commitments, and positioning t…

Speaker 1

Thank you, Paul. Operator, let's open up for questions. In order for us to take as many questions as possible, please limit yourself to one question. Operator, please go ahead.

Passages & reports (1)
  • Thank you, Paul. Operator, let's open up for questions. In order for us to take as many qu…

Speaker 0

Thank you. If you would like to ask a question, please signal by pressing star one on your telephone keypad. ?If you're using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. Again, please press star one to ask a question. We'll pause for just a moment to allow everyone an opportunity to signal for questions.

Passages & reports (3)
  • Thank you. If you would like to ask a question, please signal by pressing star one on your…
  • If
  • you're using a speakerphone, please make sure your mute function is turned off to allow yo…

Speaker 0

We'll go first to Matthew Blackman with T D. Cowan.

Passages & reports (1)
  • We'll go first to Matthew Blackman with T D. Cowan.

Speaker 4

Unverified voice label

Yes, we can. Good morning, Matt. Great. Good morning. So uh Von, it it's clear that a majority of the uh of the franchises are are performing well. So maybe can you just talk a little bit more ?about some of the successes you're seeing in in HIPS and SCT? Are these sustainable, sort of near and intermediate term uh growth rates? ?And then these, what's the path forward to get back to market growth?

And
?you know, should we be more confident in your ability to turn that business given what we're seeing in HIPS, for instance, but also uh the broader commercial initiatives you have in place. Just any color on those two topics would be great. Thanks so

Passages & reports (7)
  • Yes, we can. Good morning, Matt. Great. Good morning. So uh Von, it it's clear that a majo…
  • about
  • some of the successes you're seeing in in HIPS and SCT? Are these sustainable, sort of nea…
  • And
  • then these, what's the path forward to get back to market growth? And
  • you
  • know, should we be more confident in your ability to turn that business given what we're s…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Thanks for ?the uh thoughtful question here, Matt. So uh look, I've I've been I've been on this road now for three years, and often I get asked the question of uh what are uh what are investors missing? It's a great question considering where we are from a multiple perspective. And I'll tell you there is one thing that resonates. I think investors don't realize that we are no longer just an e-company.

We are no longer a company that is mostly a reconstructive company. So when you break uh organization into parts and pieces, uh today NICE, uh Global NICE is roughly a third of our entire book of business.
?Uh US NIS uh is around 20% of our entire book of business, and then two thirds of the company is something else. We over the last five, seven years built uh what I call a world class portfolio around SET SET, which is a lot of stuff.

You got sports, you got extremities, you got
a great CMFT business. We built what I think is the leading foot and ankle company growing eighteen percent this quarter. And we've got a great technology portfolio that raised the quarter is not growing twenty, thirty percent. So we're no longer a an e company and a lot is working really, really well on these businesses, um, as evidenced by the upper single digit of double digit growth, which to answer your question directly, I do think is sustainable.

Not not ready to commit to growing this SET business every quarter upper single uh digit like this quarter or double digit. But there is plenty of market growth in
these areas. There is plenty of innovation in these areas to continue to deliver uh significantly above uh market growth rates. Now, all of these data points is not to tell you that we don't care about NIS.

We got work to do. Uh we're not pleased with the uh US knee performance, but we
expected it. We know we got some challenges we need to address, and we're addressing those. And those are around two key areas. One is the go-to-market dynamics. We've known for a while that uh most of our reps in the US have been pretty much just doing this and little else.

We know we
got commercial execution deficits that we need to resolve. That's why we're changing incentive plans, that's why we have change leadership, that's why we are converting independent, non-direct representatives to direct. So that's one area that we're working on. And then the other one is around innovation and ?execution on bots. That's why we've done the things that we're doing. We extended our partnership with T Mini.

We launched Rosa Optimize, which is tracking very nicely. And as you heard in my paper remarks, we are getting ready for the submission of the 510K for a monogram.
?So all of this to tell you we're no longer just an e company. We're growing very nicely in two thirds of the company. By the way, global needs, excluding China, would have been flat. ?

And
we got work to do in the US, and we are doing the work and we're gonna get better. So that's the summary of all parts and pieces. Again, thanks for the thoughtful question, Matt.

Passages & reports (17)
  • Thanks for
  • the uh
  • thoughtful question here, Matt. So uh look, I've I've been I've been on this road now for …
  • that resonates. I think investors don't realize that we are no longer just an e-company. W…
  • Uh
  • US NIS uh is around 20% of our entire book of business, and then two thirds of the company…
  • a great CMFT business. We built what I think is the leading foot and ankle company growing…
  • these businesses, um, as evidenced by the upper single digit of double digit growth, which…
  • these areas. There is plenty of innovation in these areas to continue to deliver uh signif…
  • expected it. We know we got some challenges we need to address, and we're addressing those…
  • got commercial execution deficits that we need to resolve. That's why we're changing incen…
  • execution
  • on bots. That's why we've done the things that we're doing. We extended our partnership wi…
  • So
  • all of this to tell you we're no longer just an e company. We're growing very nicely in tw…
  • And
  • we got work to do in the US, and we are doing the work and we're gonna get better. So that…

Speaker 4

Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

Our next question comes from the line of Rick Wise with Stiefle.

Passages & reports (1)
  • Our next question comes from the line of Rick Wise with Stiefle.

Speaker unclear

?Good

Passages & reports (1)
  • Good

Speaker 5

Unverified voice label

morning, Yvonne. Good to see the constructive progress this quarter. Um you've given us a lot to ask about, but I I guess I have to ?I feel like I have to focus on the macro uh uh uh recon environment. ?I don't have to tell you, I'm sure you know, one of your major competitors indicated that they're seeing slower procedural growth, uh concerns about higher insurance premiums premiums and deductible, increased pre-authorization denials, et cetera, et cetera, et cetera.

Uh
?I I'm not picking up on uh on on that kind of perspective in your in your prepared remarks. How do you see the market? Uh are we stable? Are we getting worse? Uh and how are you thinking, how are you factoring all that into the outlook for this year and maybe potentially into next?

Passages & reports (8)
  • morning, Yvonne. Good to see the constructive progress this quarter. Um you've given us a …
  • I
  • feel like I have to focus on the macro uh uh uh recon environment.
  • I
  • don't have to tell you, I'm sure you know, one of your major competitors indicated that th…
  • I
  • I'm not picking up on uh on on that kind of perspective in your in your prepared remarks. …
  • next?

Speaker 2

Yeah. ?Uh thanks for uh the question. Great to uh have you with us uh this morning, Rick. Look, uh it's gonna be a bit of a repetitive uh answer. We we don't look at one quarter or even two quarters uh to claim that a market is growing or slowing down. Uh certainly some noise uh around nice, uh, but nothing really that will tell me structurally this market is changing.

I'm not sure that I'm ready to declare a market slowdown when our hip business grew seven percent globally, five point eight in the US, when a lot of categories within SET were growing double digit. And again, we have,
yes, one competitor with a lot of issues in the uh in the year. Uh, but we have another competitor growing three, four percent in US knee.

So I'm not sure that I'm ready to say, you know, this is the end of uh the NE market growing at a certain pace. We continue to
put all parts and pieces, what we call the WemGuard, at four to four and a quarter. ?Uh that number is similar in the US, uh, four to four and a quarter. Um, we like where we are in a lot of categories in set.

We also like what we see in the ASC environment where we grow in double digit. The largest ASC operator in the US just reported 13% growth in
volumes year over year. So again, I think there is plenty of data points to suggest that there may be some light shoppiness within the quarter in a certain segment, but this is by no means the uh ?the end of a market growth rate.

So Recon, we peg it to be in the US call it, you know, between two and a half to three and a half, somewhere in there. And again, we did see better performance in HIPS than than NIS. Specific to us, I would tell you that probably 90%
of our underperformance expected, but underperformance in NIS is commercial execution driven. So that's how we think uh about the market.

We we're tracking things like cancellation rates, which are pretty much steady over the last call of five years. We look at things like pricing. You know, one of the lead indicators that a
market is about to slow down is you see pretty significant price erosion. ?Uh and we saw that in 2008. We saw that uh in 2012, obviously we saw that during COVID.

Oral price and performance this quarter is actually better than last quarter. So again, we're not ready to call it a market slowdown. We got work to do around commercial execution and that's what we're gonna focus

Passages & reports (15)
  • Yeah.
  • Uh
  • thanks for uh the question. Great to uh have you with us uh this morning, Rick. Look, uh i…
  • around nice, uh, but nothing really that will tell me structurally this market is changing…
  • yes, one competitor with a lot of issues in the uh in the year. Uh, but we have another co…
  • put all parts and pieces, what we call the WemGuard, at four to four and a quarter.
  • Uh
  • that number is similar in the US, uh, four to four and a quarter. Um, we like where we are…
  • volumes year over year. So again, I think there is plenty of data points to suggest that t…
  • the
  • end of a market growth rate. So Recon, we peg it to be in the US call it, you know, betwee…
  • of our underperformance expected, but underperformance in NIS is commercial execution driv…
  • market is about to slow down is you see pretty significant price erosion.
  • Uh
  • and we saw that in 2008. We saw that uh in 2012, obviously we saw that during COVID. Oral …

Speaker unclear

?on.

Passages & reports (1)
  • on.

Speaker 5

Thank you, Ivan

Passages & reports (1)
  • Thank you, Ivan

Speaker 0

We'll go next to Patrick Wood with UBS.

Passages & reports (1)
  • We'll go next to Patrick Wood with UBS.

Speaker 1

Beautiful.

Passages & reports (1)
  • Beautiful.

Speaker 6

Unverified voice label

Uh thank you so much for taking the question. I I'd love to um jump on monogram. Obviously coming in timing wise, ?you know, ahead of where we all thought that it would. Um pretty unique platform in that way. You know, Ivan, I'd love to hear you know the strategy around the go to market, you know, how you're thinking about the initial rollout, the pace, and really communicating the value part prop to uh to surgeons.

Anything
you want to call out on monogram would be great. Thanks.

Passages & reports (4)
  • Uh thank you so much for taking the question. I I'd love to um jump on monogram. Obviously…
  • you know,
  • ahead of where we all thought that it would. Um pretty unique platform in that way. You kn…
  • you want to call out on monogram would be great. Thanks.

Speaker 2

Good morning. Uh great to have you with us. Uh look, we we're very excited. Uh at the same time, we gotta be careful what we say because this is not a a product that is being approved. Uh do expect, as I highlighted in my paper remarks, to submit the 510K very, very soon. And when I say very, very soon, I'm talking very, very soon.

We like the fact that given the clinical work that we've done around validation and verification, we can actually leap forward to a fully autonomous indication. So no longer we need to have a breach of a semi-autonomous and then move to a
fully autonomous. So that's definitely transformational.

Passages & reports (3)
  • Good morning. Uh great to have you with us. Uh look, we we're very excited. Uh at the same…
  • And when I say very, very soon, I'm talking very, very soon. We like the fact that given t…
  • fully autonomous. So that's definitely transformational.

or have validated key features around safety, very smart surgical boundaries. And by the way, if you're in Dallas later this week, I'd love for you to uh join the demonstrations that we're doing. So safety is ?one of the key competitive advantages here. In the clinical trial, we saw zero patient safety reports. We love the efficiency, second feature of the platform, fast registration, fast bone preparation.

We will try to make the claim that this will get us to time neutrality
versus conventional. So extremely efficient. Less than three minutes for bone cutting.

Passages & reports (4)
  • or have validated key features around safety, very smart surgical boundaries. And by the w…
  • one
  • of the key competitive advantages here. In the clinical trial, we saw zero patient safety …
  • versus conventional. So extremely efficient. Less than three minutes for bone cutting.

Speaker unclear

?If

Passages & reports (1)
  • If

Speaker 2

that is not enough to say on this topic, I don't know what else we can claim. Is of use. This is a robot that you don't need to have a complex surgical algorithm. You don't need to rethink your surgical algorithm. So really democratizing robotics for the masses. Highly reproducible, the fourth claim. And then we've seen in a lot of the clinical work we've done, we've seen a reduction or an improvement rather in accuracy.

So again, safety, efficiency, ease of use, reproducibility, and accuracy are the five key claims. Today in the US, roughly 80% of surgeons don't use a robot for a variety of reasons. That
number is close to 90% outside the US. So we see a dramatic opportunity to focus on the blue ocean opportunity of those surgeons that are not using a robot. Then obviously we believe that this will be second segment, an opportunity for us to convert comparative accounts.

In the US, CPS scanning is a
must. Ease of use is a must. And again, I'm not gonna repeat the whole speech I just gave you. We we're gonna get that done through a monogram. And then there'll be a third segment of some Rosa users that in the US may wanna wanna wanna move to um to monogram. That that is not the primary segment.

Rosa is gonna continue to be part of the portfolio and we're very, very excited about the monogram. So again, if you're in Dallas, love to see you there. We're very excited about where we are with this with this platform. Thanks.

Passages & reports (5)
  • that is not enough to say on this topic, I don't know what else we can claim. Is of use. T…
  • then we've seen in a lot of the clinical work we've done, we've seen a reduction or an imp…
  • number is close to 90% outside the US. So we see a dramatic opportunity to focus on the bl…
  • must. Ease of use is a must. And again, I'm not gonna repeat the whole speech I just gave …
  • is not the primary segment. Rosa is gonna continue to be part of the portfolio and we're v…

Speaker 6

Love it. Thank

Passages & reports (1)
  • Love it. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

We'll go next to Vijay Kumar with Evercore ISI.

Passages & reports (1)
  • We'll go next to Vijay Kumar with Evercore ISI.

Speaker unclear

?Hi Yvonne good morning and thank you for taking my question. And congrats on nice print this morning.

Passages & reports (1)
  • Hi Yvonne good morning and thank you for taking my question. And congrats on nice print th…

Speaker 7

Unverified voice label

I guess um I had one on um the Outlook uh kind of question. ?You know roughly guidance for 26, S3.25% at the midpoint that includes China headwinds and your Salesforce transition headwinds rate. When you think about 27%, why wouldn't 27% get better versus the 3.25 for 26? Or should we be thinking of uh other one-off items and any any other go-to-market um um strategy change, or perhaps the Salesforce transition headwinds accelerating into next year?

Any variables you could point out to for 27 will be helpful.

Passages & reports (4)
  • I guess um I had one on um the Outlook uh kind of question.
  • You know
  • roughly guidance for 26, S3.25% at the midpoint that includes China headwinds and your Sal…
  • and any any other go-to-market um um strategy change, or perhaps the Salesforce transition…

Speaker 2

Yes, thanks, Vijay. As you can expect, we're not gonna get into uh a lot of detail here on twenty seven. So I'm just gonna repeat the things that I said publicly uh in the past. Um a better year compared to uh 2026, and and that's based on some obvious factors. Uh we've been very public about the noise in China. Uh China is two percent of the revenue of the company, one percent of the evidence of the company, but it's been declining uh at uh massive rates in 2026, given all the changes that we have implemented in the country.

This quarter, China cost us a hundred basis points of growth. This quarter that'd be in Q three. And in Q four, it's gonna cost us another a hundred basis points. For the year is 50 basis points. So obviously, that's something that in
January of 2027 anniversaries. Then the second major tailwind in 207 is gonna be monogram. And again, we're not gonna comment on whether we get three quarters, two quarters, or what's gonna be, but the expectation is that that's gonna be a catalyst. ?

Uh
Paragon 28 uh in 2027 ?is gonna be a full year of organic growth versus uh a couple of quarters plus in 2026. So again, that's a platform that is growing close to 20%. ?Uh we don't see that slowing down, so again, we get a full year benefit ?there. Uh so those are three very obvious uh factors that uh lead us to believe that twenty seven will be better.

Not to mention that obviously a lot of the work we've made or a lot of the work that we've undertaken
?in the go to market changes in the US will will benefit in in twenty seven. At the same time, as always, there'll be um some headwinds that we're gonna have to manage. Uh and again in early twenty seven we'll talk about those headwinds and tailwinds and what the guidance looks like.

What I will
leave you with is that uh we're gonna be very consistent. ?Uh once we provide guidance in twenty seven, we're gonna be very consistent with the philosophy uh that uh we got here or the philosophy that we have for twenty twenty six. We're gonna take a measured approach as we did uh for twenty six ?and the goal will be as always to uh exceed expectations to say less and to do more so that's the call or that I'll offer on twenty twenty seven.

Thanks for the question, BJ.

Passages & reports (19)
  • Yes, thanks, Vijay. As you can expect, we're not gonna get into uh a lot of detail here on…
  • a better year compared to uh 2026, and and that's based on some obvious factors. Uh we've …
  • given all the changes that we have implemented in the country. This quarter, China cost us…
  • January of 2027 anniversaries. Then the second major tailwind in 207 is gonna be monogram.…
  • Uh
  • Paragon 28 uh in 2027
  • is
  • gonna be a full year of organic growth versus uh a couple of quarters plus in 2026. So aga…
  • Uh
  • we don't see that slowing down, so again, we get a full year benefit
  • there. Uh
  • so those are three very obvious uh factors that uh lead us to believe that twenty seven wi…
  • in
  • the go to market changes in the US will will benefit in in twenty seven. At the same time,…
  • leave you with is that uh we're gonna be very consistent.
  • Uh
  • once we provide guidance in twenty seven, we're gonna be very consistent with the philosop…
  • and
  • the goal will be as always to uh exceed expectations to say less and to do more so that's …

Speaker unclear

?That's helpful. Thank you.

Passages & reports (1)
  • That's helpful. Thank you.

Speaker 0

We'll go next to Travis Steed with Bank of America.

Passages & reports (1)
  • We'll go next to Travis Steed with Bank of America.

Speaker 6

Hey thanks for the question.

Passages & reports (1)
  • Hey thanks for the question.

Speaker unclear

?You know you were been talking about getting the six percent market growth rate by the end of the decade so likely going gonna take uh MA. And so just curious how you're thinking about the MA environment, the willingness to

Passages & reports (1)
  • You know you were been talking about getting the six percent market growth rate by the end…

Speaker 2

kind

Passages & reports (1)
  • kind

Speaker unclear

?of take solution right now. Um, and then even excluding uh MA, like how do you think about the ability

Passages & reports (1)
  • of take solution right now. Um, and then even excluding uh MA, like how do you think about…

Speaker 2

to get EPS leverage next year? Is ?you know, is this a year where EPS is probably more ?in line with revenue growth or is their ability to grow EPS ?faster, given that's kind of where the street's modeling today?

Passages & reports (7)
  • to get EPS leverage next year? Is
  • you
  • know, is this a year where EPS is probably more
  • in
  • line with revenue growth or is their ability to grow EPS
  • faster,
  • given that's kind of where the street's modeling today?

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

I'll start with the second one. Uh the simple answer is we'll talk about EPS leverage in 27 in 27. So there's gonna be a lot of moving parts and pieces. You know, you got tailwinds, headwinds. So again, EPS, let's leave that for the early 2027 goal. On the aspiration of 6% wim guard, uh, we don't need to do that uh entirely in an inorganic way. ?

Uh
as you heard in my prepared remarks, there's a couple of uh pathways to get ?there. Uh we have reshuffled the RD investments for the last three, five years towards higher growth environments. That is one major reason of why our SET business is growing at the rate that it's growing. The last data point that we offer externally is that 85 to 90 percent of our o of our R D is in markets growing north of uh five-six percent.

So again, organically we're getting
?there. Then we have this partnership with uh Deerfield and HSS with a lot of investments in really high growth areas. ?Uh we recently launched strategic ventures making investments uh from a Debco standpoint in high growth areas. So again, there is a lot of things that we're doing ?uh organically and inorganically, not just buying companies. All of that said, yeah, uh MA, responsible MA will be part of the uh of the equation.

Uh this company has now operating cash flows nearing two billion per year.
?Uh operating cash flow is close to one point three, or free cash flow is close to one point three. Free cash flow conversion in the quarter was north of a hundred percent. Uh year to day 77%. So very proud of the work we're doing around cash. And now we're going to put the cash to work.

In 26, it's been around buybacks primarily. In 2027, we'll be doing responsible MA. And the formula, the algorithm, has not changed. We're going to focus on high growth segments of Recon. Similar deals such as orthogrid, monogram, hammer at one point. The
second area of focus is going to be higher growth areas within SCP. We love the acquisition of Paragon 28. We love what we done with Embody, with AE, in CMFT, JS Medical.

So a lot of deals that we don't talk about that we done in SCP that are working very nicely. So that's
?the second area. ?And then we look at adjacencies. We look at things like what happens in an ASC environment given the migration there. ?So those are the three key areas: high growth segments in Recon, high growth areas in SCT, and then we look at adjacencies.

Financially, um, the same um the same algorithm as
?well. Uh ideally up to two billion dollars in acquisition price. Uh whatever we acquire has to be obviously immediately revenue and WemGuard accredited. ?Uh similar to Paragon twenty eight, EPS accreditive by the second year, ?uh but in a year two. And then we're gonna target acquisitions that will provide uh double digit ROIC return on investment capital by year by year five.

So we're gonna be very disciplined around the deals around the where we invest, but also the deals in terms of the financial returns. And
again, uh we got a great proxy now with Paragon 28 that is working above expectations. So the level of confidence is very high that we can uh reload and do another strategic deal again.

Passages & reports (30)
  • I'll start with the second one. Uh the simple answer is we'll talk about EPS leverage in 2…
  • uh, we don't need to do that uh entirely in an inorganic way.
  • Uh
  • as you heard in my prepared remarks, there's a couple of uh pathways to get
  • there.
  • Uh we have reshuffled the RD investments for the last three, five years towards higher gro…
  • D is in markets growing north of uh five-six percent. So again, organically we're getting
  • there.
  • Then we have this partnership with uh Deerfield and HSS with a lot of investments in reall…
  • Uh
  • we recently launched strategic ventures making investments uh from a Debco standpoint in h…
  • uh
  • organically and inorganically, not just buying companies. All of that said, yeah, uh MA, r…
  • Uh
  • operating cash flow is close to one point three, or free cash flow is close to one point t…
  • to work. In 26, it's been around buybacks primarily. In 2027, we'll be doing responsible M…
  • second area of focus is going to be higher growth areas within SCP. We love the acquisitio…
  • the
  • second area.
  • And
  • then we look at adjacencies. We look at things like what happens in an ASC environment giv…
  • So
  • those are the three key areas: high growth segments in Recon, high growth areas in SCT, an…
  • well.
  • Uh ideally up to two billion dollars in acquisition price. Uh whatever we acquire has to b…
  • Uh
  • similar to Paragon twenty eight, EPS accreditive by the second year,
  • uh
  • but in a year two. And then we're gonna target acquisitions that will provide uh double di…
  • again, uh we got a great proxy now with Paragon 28 that is working above expectations. So …

Speaker unclear

?Great. Thank you.

Passages & reports (1)
  • Great. Thank you.

Speaker 0

We'll go next to Robbie Marcus with JP Morgan.

Passages & reports (1)
  • We'll go next to Robbie Marcus with JP Morgan.

Speaker unclear

?Good

Passages & reports (1)
  • Good

Speaker 2

morning and uh congrats on a good quarter. Um Yvonne may maybe um it I'm just looking at headlines um from the Democrats that they'll seek to reverse Medicaid cuts and restore ECA

Passages & reports (1)
  • morning and uh congrats on a good quarter. Um Yvonne may maybe um it I'm just looking at h…

Speaker unclear

?subsidies. How do you think the

Passages & reports (1)
  • subsidies. How do you think the

Speaker 2

negative cuts to

Passages & reports (1)
  • negative cuts to

Speaker unclear

?health care in the U.S. have impacted your and

Passages & reports (1)
  • health care in the U.S. have impacted your and

Speaker 2

markets? Where

Passages & reports (1)
  • markets? Where

Speaker unclear

?do you think your weight average and market growth is right now,

Passages & reports (1)
  • do you think your weight average and market growth is right now,

Speaker 2

given

Passages & reports (1)
  • given

Speaker unclear

?some of the the changes in in the knee and market. And you know, how are you thinking about weight average and market growth going forward and how much does that change it if the uh healthcare cuts are reversed? Thanks a lot.

Passages & reports (1)
  • some of the the changes in in the knee and market. And you know, how are you thinking abou…

Speaker 2

Hey thank you Robbie. Look, uh obviously too early to start discussing what's gonna happen here with the Senate and and and and and the House here and and look we'll we'll talk about it when we get more information. So I I'm gonna talk about what I know. We We know and we validated this externally that our global Wengar is around four to four and a quarter.

We've also validated that it's a similar number here in the US. Even if you go with the Barry's case that our Recon business in the US
?is moving towards the two and a half that competitors are claiming, or the three and a half that we believe is uh the reality in the US, we still see a Wengar environment of four to uh to four a and a and a quarter. ?

Uh
ACA subsidies, we've not seen a material impact. As a reminder, the average patient that goes through procedures is 64, 65 years of age. So that's a a Medicare patient. As of right now, the expectation is that Medicare reimbursement will go up in early 2027.

Passages & reports (6)
  • Hey thank you Robbie. Look, uh obviously too early to start discussing what's gonna happen…
  • this externally that our global Wengar is around four to four and a quarter. We've also va…
  • is
  • moving towards the two and a half that competitors are claiming, or the three and a half t…
  • Uh
  • ACA subsidies, we've not seen a material impact. As a reminder, the average patient that g…

Speaker 2

Pricing is moving in the right direction. The implant price as a percentage of the DRG is at an all time low. So I will tell you right now, the variables that we look at const continue to be very healthy. So we'll we'll see what happens with everything that happened last night here in the US. But uh again, as a reminder, we do more than selling hips and knees to patients in the US.

Thanks for the question.

Passages & reports (2)
  • Pricing is moving in the right direction. The implant price as a percentage of the DRG is …
  • the US. But uh again, as a reminder, we do more than selling hips and knees to patients in…

Speaker 1

Thanks, Ivan.

Passages & reports (1)
  • Thanks, Ivan.

Speaker 0

Our next question comes from the line of Larry Biggleson with Wells Fargo.

Passages & reports (1)
  • Our next question comes from the line of Larry Biggleson with Wells Fargo.

Speaker 1

Thanks for taking the question.

Passages & reports (1)
  • Thanks for taking the question.

Speaker unclear

?Hey Yvonne, um there's obviously been a lot of

Passages & reports (1)
  • Hey Yvonne, um there's obviously been a lot of

Speaker 7

media reports of private equity interest in certain ortho businesses and potential combinations of

Passages & reports (1)
  • media reports of private equity interest in certain ortho businesses and potential combina…

Speaker 1

uh ortho businesses.

Passages & reports (1)
  • uh ortho businesses.

Speaker 7

How is this media speculation affecting Zimmer and its employees? And how are you thinking about potential options in light of all this interest we're reading

Passages & reports (1)
  • How is this media speculation affecting Zimmer and its employees? And how are you thinking…

Speaker unclear

?about?

Passages & reports (1)
  • about?

Speaker 2

Hey, thank you, uh Larry. Uh obviously I'm not gonna get into a lot of speculation around the the deals that are happening elsewhere. What I'll tell you is that our employees are laser focused on driving growth. And uh and you've seen that in the print for the quarter, where again two thirds of our book of business is growing upper single digit, double digit.

In the US, we deliver growth approaching four percent. I like what we are in the US uh year to date growing at 3.8%. Uh I like the fact that our turnover in the US is single digit. Uh we love the fact that
the transformation of the channel is going better than expected. So clearly the focus is there, the performance is there. Uh disruption in other parts uh and pockets of MedTech.

Uh we'll leverage that when we
?can. We continue to hire uh tremendous amount of people from great companies. And uh right now we are laser focused. As far as what others are doing in terms of private equity and whatnot, we're not gonna we're not gonna get into a lot of detail there. We're just gonna continue to do what we're doing, which is to focus on innovation and commercial execution.

Thank you, Larry.

Passages & reports (6)
  • Hey, thank you, uh Larry. Uh obviously I'm not gonna get into a lot of speculation around …
  • our book of business is growing upper single digit, double digit. In the US, we deliver gr…
  • the transformation of the channel is going better than expected. So clearly the focus is t…
  • can.
  • We continue to hire uh tremendous amount of people from great companies. And uh right now …
  • doing, which is to focus on innovation and commercial execution. Thank you, Larry.

Speaker unclear

?Uh hi,

Passages & reports (1)
  • Uh hi,

Speaker 7

thanks for taking the question.

Passages & reports (1)
  • thanks for taking the question.

Speaker unclear

?Um I wanted to ask one on monogram. I know you're not gonna talk about the contribution in twenty twenty seven, but maybe you could give us some updated thoughts longer term on the kind of share you think

Passages & reports (1)
  • Um I wanted to ask one on monogram. I know you're not gonna talk about the contribution in…

Speaker 2

monogram ?could could drive towards Zimmer or just other ?ways to think about the growth driven by monogram as

Passages & reports (5)
  • monogram
  • could
  • could drive towards Zimmer or just other
  • ways to think
  • about the growth driven by monogram as

Speaker unclear

?it complements the rest of your robotic strategy.

Passages & reports (1)
  • it complements the rest of your robotic strategy.

Speaker 2

Hey, thank you. Uh look, we we expect uh monogram to be a mayor catalyst uh for the company. I know we're not ready to talk about what is the meaning 27 or beyond. But I'll bring you right back as we think about modeling the opportunity, I'll bring you right back to those three segments that I was talking about. 90% of uh surgeons outside of the US don't use a robot.

And if you bring a robot that is gonna drive efficiency, accuracy, with a great safety profile, and the economic and clinical benefits can get validated, I do think the number is gonna increase. There'll be more
surgeons outside of the US where they'll jump on a robotic platform. And in the US, even with the great work uh that we've done here, still uh only 20% of surgeons ?uh are using a robot.

So you get an 80%
?uh blue ocean opportunity. So as you can imagine, we spend a lot of time in understanding what it is that we need to do to drive more adoption. Uh beyond that, we we've not done the job that we could have done when it comes to uh converting accounts. We've done some of ?it, uh, but for a variety of reasons, we we've not been able to gain meaningful share from competitors.

I believe, we believe that monogram, given everything that we have seen, changes that dynamic. So that's those are the two key buckets that I leave you with as you model the uh the opportunity. Beyond that, it's
not just monogram, right? I keep talking about the suite of solutions. Today we have the most comprehensive suite of solutions in technology. Uh if you want a CT scan platform, we have it.

If you don't want to do CT scanning, which is the preferred uh surgical uh algorithm, the preferred formula outside the
US, we have that as well. If you wanna have a large footprint robot, we have it. If you wanna have a smaller one, we have it. If you don't wanna do robotics and you wanna do navigation, we have all forms of navigation, from orthogrid uh to FDA approved mixed reality.

So it's much
more than uh monogram. But that said, ?we believe that the monogram opportunity is gonna be very compelling. Not to mention that now we're gonna have a best-in-class robot with the world's number one uh orthopedic implant. We're moving very fast on making sure this is not just a one indication uh platform uh or robot. We expect to have the partial knee and the hip application and the solar application uh at a very rapid pace.

So again, lots of excitement as
?as you can imagine when it comes to monogram. And I hope uh once again I hope you're gonna be in Dallas so we can share more about this uh launch. Thank

Passages & reports (17)
  • Hey, thank you. Uh look, we we expect uh monogram to be a mayor catalyst uh for the compan…
  • segments that I was talking about. 90% of uh surgeons outside of the US don't use a robot.…
  • surgeons outside of the US where they'll jump on a robotic platform. And in the US, even w…
  • uh
  • are using a robot. So you get an 80%
  • uh
  • blue ocean opportunity. So as you can imagine, we spend a lot of time in understanding wha…
  • it, uh,
  • but for a variety of reasons, we we've not been able to gain meaningful share from competi…
  • not just monogram, right? I keep talking about the suite of solutions. Today we have the m…
  • US, we have that as well. If you wanna have a large footprint robot, we have it. If you wa…
  • more than uh monogram. But that said,
  • we
  • believe that the monogram opportunity is gonna be very compelling. Not to mention that now…
  • and the hip application and the solar application uh at a very rapid pace. So again, lots …
  • as
  • you can imagine when it comes to monogram. And I hope uh once again I hope you're gonna be…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Great. Thanks so

Passages & reports (1)
  • Great. Thanks so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 0

We'll go next to Richard Neueter with Truist.

Passages & reports (1)
  • We'll go next to Richard Neueter with Truist.

Speaker unclear

?Hi, thanks for taking the question. Um and and congrats on the progress this quarter. I guess

Passages & reports (1)
  • Hi, thanks for taking the question. Um and and congrats on the progress this quarter. I gu…

Speaker 2

I just

Passages & reports (1)
  • I just

Speaker unclear

?wanted to get a better feel

Passages & reports (1)
  • wanted to get a better feel

Speaker 2

for

Passages & reports (1)
  • for

Speaker unclear

?because it sounds like you

Passages & reports (1)
  • because it sounds like you

Speaker 2

have

Passages & reports (1)
  • have

Speaker unclear

?kind of two things that

Passages & reports (1)
  • kind of two things that

Speaker 2

should lead ?to an exc three things lead to

Passages & reports (3)
  • should lead
  • to an exc three
  • things lead to

Speaker unclear

?an acceleration of needs at some point next

Passages & reports (1)
  • an acceleration of needs at some point next

Speaker 2

year. Uh you know, one

Passages & reports (1)
  • year. Uh you know, one

Speaker unclear

?you have easier easy comps, two, you you have monogram coming uh and that's getting pulled forward. And then three, there's the Salesforce changes that you know you're making that are clearly having impact in other parts of the

Passages & reports (1)
  • you have easier easy comps, two, you you have monogram coming uh and that's getting pulled…

Speaker 6

business, I would imagine, sooner than they're actually showing up in these. ?So the

Passages & reports (3)
  • business, I would imagine, sooner than they're actually showing up in these.
  • So
  • the

Speaker unclear

?question is when can we expect to start to see you realistically US knee acceleration show up next year?

Passages & reports (1)
  • question is when can we expect to start to see you realistically US knee acceleration show…

Speaker 2

And is

Passages & reports (1)
  • And is

Speaker unclear

?it

Passages & reports (1)
  • it

Speaker 6

entirely based on monogram adoption or ?or or can we start to see you know ?easy c easier comps

Passages & reports (5)
  • entirely based on monogram adoption or
  • or
  • or can we start to see you know
  • easy
  • c easier comps

Speaker unclear

?and some of the Salesforce impact actually show up on improved knee performance? Thanks.

Passages & reports (1)
  • and some of the Salesforce impact actually show up on improved knee performance? Thanks.

Speaker 2

Thank you. So let me let me break those three things here for you. So obviously the comms are the comms. So you you're right in that regard. ?Uh on your second point on monogram, uh, look, we we gotta get an approval first. You know, filing a five ten K does not mean an approval. So let us go through the work and then we'll know what is the impact of monogram in 2027. ?

And
then on the Salesforce, this is uh a tell of two cities, right? On the one side, you will see the benefit of some of the changes that we made in uh twenty 2026. Uh we've been very public uh around the fact that it takes you know 12 to 18 months to see the benefit. So yeah, a a lot of the work in 26 becomes a tailwind in 2027.

At the same time we've also been very public around the fact that the third stage of this code of market transformation is the riskiest, which is the one that we're going through right now. So hard to quantify
at this point what's gonna be the uh the balance between the the tailwind and the and the headwind. ?But but you're right about those three things.

Um so we do expect that NEETs will perform better at some point. We're not ready to commit exactly in what quarter, but the expectation is that NEETs will improve. But but no it's not just you know one or two things. It's uh probably broader than
?that. Thank you.

Passages & reports (11)
  • Thank you. So let me let me break those three things here for you. So obviously the comms …
  • Uh
  • on your second point on monogram, uh, look, we we gotta get an approval first. You know, f…
  • And
  • then on the Salesforce, this is uh a tell of two cities, right? On the one side, you will …
  • benefit. So yeah, a a lot of the work in 26 becomes a tailwind in 2027. At the same time w…
  • at this point what's gonna be the uh the balance between the the tailwind and the and the …
  • But
  • but you're right about those three things. Um so we do expect that NEETs will perform bett…
  • that.
  • Thank you.

Speaker 0

Our next question comes from the line of Chris Pascual with Barclays.

Passages & reports (1)
  • Our next question comes from the line of Chris Pascual with Barclays.

Speaker unclear

?Thanks. Um

Passages & reports (1)
  • Thanks. Um

Speaker 5

Yvonne you mentioned ?you're about halfway

Passages & reports (3)
  • Yvonne you mentioned
  • you're
  • about halfway

Speaker 6

through the

Passages & reports (1)
  • through the

Speaker 2

Salesforce re organization and so far the disruption's been less than expected. As you think about bringing that process to a close and it sounded like you hinted to this a little bit with uh the response to the last question,

Passages & reports (1)
  • Salesforce re organization and so far the disruption's been less than expected. As you thi…

Speaker 5

how

Passages & reports (1)
  • how

Speaker 2

much is ?is it really de-risk? Did you start with the easiest parts ?and now the tough pieces are left?

Passages & reports (5)
  • much is
  • is it
  • really de-risk? Did you start with the easiest parts
  • and now
  • the tough pieces are left?

Speaker 5

Can

Passages & reports (1)
  • Can

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 2

apply what you've learned so far to to mitigate the the risk going forward? ?Would just love any color you can provide as we think about the potential impact from that piece in twenty seven. Sure. Look um it's working better than expected.

Passages & reports (3)
  • apply what you've learned so far to to mitigate the the risk going forward?
  • Would
  • just love any color you can provide as we think about the potential impact from that piece…

I refer you to the growth in the quarter, uh 3.6 uh growth in the US, 5.8 in hips. ?Uh we delivered, I think it was 32% growth in uh data and technology. That's the people that we that we add ?in. Uh we really don't talk about the SET number in the US, but it was mid-single digit. ?Uh in the north side of mid single digit.

So again, the numbers reflect the fact that this is working better than expected. Uh low single digit or single-digit turnover.
?Uh we're doing all the right things. Um what are we learning? We're learning that we got to go at a certain pace. And we are doing that. You know, we've always talked about the three stages of the transformation. Stage one was the low-risk, low-hanging fruit.

So, no, we did not start with the riskiest,
that's done. The second stage was moderate risk, uh, which we close. ?Uh, and now we are early in the third stage with the higher risk. Um, so that's that's what we are right now in terms of the uh the three stages. We very much believe that this project is manageable. We're not being pennywise pumpfulist.

You see that we're making compelling investments. That's why
?you know our EPS growth is no higher than what it was in the quarter. We're going to continue to that. We're going to invest to make sure that we de-risk the uh the project. We recently appointed Todd Becker. ?Uh Todd Becker was the number one distributor in the US as the key leader uh running this uh this project.

We call the project Optima internally.
?Uh Tori's doing a heck of a nice job here. So I will tell you, Chris, that the governance is there, the leadership is there, the investments are there. How we're thinking about stage indeed uh staging the project uh it's worked out very, very well. ?Um but we got one final stage to go through which is the higher risk.

And that's what we're
?at. Thank

Passages & reports (22)
  • I refer you to the growth in the quarter, uh 3.6 uh growth in the US, 5.8 in hips.
  • Uh
  • we delivered, I think it was 32% growth in uh data and technology. That's the people that …
  • in.
  • Uh we really don't talk about the SET number in the US, but it was mid-single digit.
  • Uh
  • in the north side of mid single digit. So again, the numbers reflect the fact that this is…
  • Uh
  • we're doing all the right things. Um what are we learning? We're learning that we got to g…
  • that's done. The second stage was moderate risk, uh, which we close.
  • Uh,
  • and now we are early in the third stage with the higher risk. Um, so that's that's what we…
  • you
  • know our EPS growth is no higher than what it was in the quarter. We're going to continue …
  • Uh
  • Todd Becker was the number one distributor in the US as the key leader uh running this uh …
  • Uh
  • Tori's doing a heck of a nice job here. So I will tell you, Chris, that the governance is …
  • Um
  • but we got one final stage to go through which is the higher risk. And that's what we're
  • at.
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 4

Thanks.

Passages & reports (1)
  • Thanks.

Speaker 0

We'll go next to Caitlin Roberts with Canacor Genuity. Great.

Passages & reports (1)
  • We'll go next to Caitlin Roberts with Canacor Genuity. Great.

Speaker unclear

?Thanks so much for taking the question. Just on the Think Agreement, any changes to note in the extension there and how's the launch going and

Passages & reports (1)
  • Thanks so much for taking the question. Just on the Think Agreement, any changes to note i…

Speaker 0

seeing anything

Passages & reports (1)
  • seeing anything

Speaker unclear

?from handheld competition in the marketplace?

Passages & reports (1)
  • from handheld competition in the marketplace?

Speaker 2

Thanks for the question. We love the partnership with uh with Think Surgical and T-Mini. Uh we just extended uh the partnership. We believe that a cordless portable robot, ?uh cordless being the key highlight CT scan base is a NET. So we now have this exclusive distribution agreement, which we extended. We can use it with the number one implant in the world, that being persona knee.

We love the fact that the CT technology is extremely smart with an active overhead
tracking, everything that's happening in the procedure, with unrestricted patient access. It's very easy to integrate the actual surgical algorithm or the technology into the surgical algorithm. One of the key claims that we continue to hear from surgeons is that it takes minimum operating room setup. So in a world of ASEs, this is a massive opportunity.

We just had a very strong quarter, Q3, in technology. A lot of that had to do with the team in its sales. So again, we love the partnership. We love the people that we work with. We love the fact that this complements our portfolio. So we don't see
an end to this partnership. We like uh where we're at, and we look forward to continuing to update you on the progress.

Thank

Passages & reports (6)
  • Thanks for the question. We love the partnership with uh with Think Surgical and T-Mini. U…
  • uh
  • cordless being the key highlight CT scan base is a NET. So we now have this exclusive dist…
  • tracking, everything that's happening in the procedure, with unrestricted patient access. …
  • this is a massive opportunity. We just had a very strong quarter, Q3, in technology. A lot…
  • an end to this partnership. We like uh where we're at, and we look forward to continuing t…

Speaker unclear

?you. Thanks.

Passages & reports (1)
  • you. Thanks.

Speaker 0

Our next ?our next question comes from the line of Steve Lichtman with William Blair.

Passages & reports (3)
  • Our next
  • our
  • next question comes from the line of Steve Lichtman with William Blair.

Speaker unclear

?Thank you. Uh morning. Um, Yvonne, you talked about

Passages & reports (1)
  • Thank you. Uh morning. Um, Yvonne, you talked about

Speaker 6

OpEx uh being an area where you're where you're looking to drive improvement. Just wondering what the levers uh you see to drive that. You know, I know you have

Passages & reports (1)
  • OpEx uh being an area where you're where you're looking to drive improvement. Just wonderi…

Speaker unclear

?obviously a lot going on with the sales transition and investment in robot sales specialists. Do

Passages & reports (1)
  • obviously a lot going on with the sales transition and investment in robot sales specialis…

Speaker 6

you

Passages & reports (1)
  • you

Speaker unclear

?see leverage coming through after getting through those processes? Anything else that you're focused on looking ahead? Thanks.

Passages & reports (1)
  • see leverage coming through after getting through those processes? Anything else that you'…

Speaker 2

Yeah, uh, thank you. I'll throw a couple of bullet points and then we'll let uh Paul comment here on the different uh vectors of opportunity. I'll start with the fact that uh in May of 2027, we're gonna celebrate 100 years in the business, ?and our OPEC still is roughly 46, 46.5%. So certainly there's an opportunity here to drive efficiencies. You know, roughly of the three point eight billion dollars in OPEX, uh a billion is uh variable compensation.

So you got two point eight billion dollars of things that we're looking at. To that extent we we're partnering
with sophisticated partners in AI implementation that are looking at what are things that we can work on around re engineering processes, uh, what are opportunities for us to drive revenue, given the fact that we collect more data than any other company for sure and orthopedics, we're looking at transactional work.

Passages & reports (4)
  • Yeah, uh, thank you. I'll throw a couple of bullet points and then we'll let uh Paul comme…
  • and
  • our OPEC still is roughly 46, 46.5%. So certainly there's an opportunity here to drive eff…
  • with sophisticated partners in AI implementation that are looking at what are things that …

There's a lot of uh opportunity when you look at search services, how we do things from a demand planning standpoint, how we engage in customer uh customer services or customer service. So a a lot of ?a lot of opportunities there that we'll update you on. But uh Paul, you want to talk about different uh parts and pieces here?

Passages & reports (3)
  • There's a lot of uh opportunity when you look at search services, how we do things from a …
  • a
  • lot of opportunities there that we'll update you on. But uh Paul, you want to talk about d…

Speaker 3

Sure, sure. That's technology will be a big part of it. We we also we've recently opened up a global capability center uh in India that's gonna allow us to kind of leverage um the cost base there, get some very, very great talent to help drive some of the different initiatives with within the business. Um that that's something that actually Yvonne was there recently, had a chance to visit the team.

Uh we're up and running and things are in great shape. You know, as we've looked at the uh with Project Optima, a lot of the investments that we've been making, um, some of those kind of
stay with us for in the near term, but they'll start to anniversary out at some point. So that's gonna provide some level of operating leverage as we go through.

And then look at the at the end, it's just good old-fashioned efficiency, right? It's continuous improvement. We've got some great teams that can can
sit in and drive process efficiency, leveraging the data that we have so that we can just do things on a more cost effective basis. So good opportunities and we're looking forward to ?it. Thank you both.

Passages & reports (6)
  • Sure, sure. That's technology will be a big part of it. We we also we've recently opened u…
  • business. Um that that's something that actually Yvonne was there recently, had a chance t…
  • stay with us for in the near term, but they'll start to anniversary out at some point. So …
  • sit in and drive process efficiency, leveraging the data that we have so that we can just …
  • it. Thank
  • you both.

Speaker 7

Thanks

Passages & reports (1)
  • Thanks

Speaker unclear

?guys.

Passages & reports (1)
  • guys.

Speaker 0

Our final question will come from Jason Bedford from Raymond James.

Passages & reports (1)
  • Our final question will come from Jason Bedford from Raymond James.

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 7

guys it's back on for

Passages & reports (1)
  • guys it's back on for

Speaker unclear

?Jason. Thanks for taking the question. Just a quick one here for you. Can you guys update us on your large joint traction into the ASC setting and then also the stability of the implant pricing in the channel?

Passages & reports (1)
  • Jason. Thanks for taking the question. Just a quick one here for you. Can you guys update …

Speaker 2

Absolutely. I didn't quite catch the second part, but uh let me answer the first one and then maybe you can uh ask the second part again. Uh ASCs today, roughly uh growth in the uh in the space for us in large zones is um upper single digit, if not double digit in in in the uh case of HIPS on set, we're growing very nicely.

And I don't remember the actu the actual breakdown, but uh I I will tell you it's
?you know in some categories double digit as well, ?uh foot and ankle, upper extremities for sure, sports medicine. So we like the migration to uh ASC. Uh roughly around 25% of a book of business today is going to an ASC. We've seen double digit growth in that regard.

Uh technology, uh the efficiency we run with technology is a major competitive advantage.
So that's another tailwind as we think about the ashift to the uh to the ASE. So we like what we ?add. And then uh can you uh can you ask again the second uh second question?

Passages & reports (9)
  • Absolutely. I didn't quite catch the second part, but uh let me answer the first one and t…
  • in the uh case of HIPS on set, we're growing very nicely. And I don't remember the actu th…
  • you
  • know in some categories double digit as well,
  • uh
  • foot and ankle, upper extremities for sure, sports medicine. So we like the migration to u…
  • So that's another tailwind as we think about the ashift to the uh to the ASE. So we like w…
  • add. And
  • then uh can you uh can you ask again the second uh second question?

Speaker 7

Sure, yeah, just

Passages & reports (1)
  • Sure, yeah, just

Speaker unclear

?the stability of

Passages & reports (1)
  • the stability of

Speaker 2

implant pricing uh ?into the ASE channel. Oh, okay, got it. Thank you. Well, look, as uh referenced earlier, uh the implant cost today as a percentage of DRG is at the lowest point in 22 years. So we don't think there is more to squeeze in in that regard. When you look at the bundle of care in orthopedics, the implant is actually less than fifteen percent.

The other eighty-five percent are things around efficiency, labor costs, readmissions, sending patients that don't need to be sent to uh
?to an inpatient unit uh post procedure. So when you're working with a company that's thinking holistically at the entire around the entire episode of care, that's a com competitive advantage. We very much look forward to January of twenty twenty eight, ?uh when CGRX uh kicks ?in.

So we we believe that the current pricing dynamic uh is uh is steady. Or um our price erosion in the third quarter was 70 basis points, which is 10 basis points better than the second quarter.
?Uh the guide that we provide for the year was flat to 100 basis points. We're very extremely confident that uh we're gonna obviously deliver on that guidance.

And as we look at 27-28, and we have a lot of lead indicators, a lot of data, we don't see anything that dramatically changes our perspective on
pricing. So we like where we're ?at. Thank

Passages & reports (15)
  • implant pricing uh
  • into the ASE channel.
  • Oh, okay, got it. Thank you. Well, look, as uh referenced earlier, uh the implant cost tod…
  • is actually less than fifteen percent. The other eighty-five percent are things around eff…
  • to
  • an inpatient unit uh post procedure. So when you're working with a company that's thinking…
  • uh
  • when CGRX uh kicks
  • in.
  • So we we believe that the current pricing dynamic uh is uh is steady. Or um our price eros…
  • Uh
  • the guide that we provide for the year was flat to 100 basis points. We're very extremely …
  • pricing. So we like where we're
  • at.
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

This concludes today's question and answer session. I would like to turn the call back over to Ivan Turnos for any closing remarks.

Passages & reports (1)
  • This concludes today's question and answer session. I would like to turn the call back ove…

Speaker 2

Thank you. We uh started the uh the call this morning with gratitude. Uh, I want to close with gratitude. Uh gratitude to the 17,000 plus team members here at Simberbaume who are doing a stellar job in delivering on our mission of alleviating pain and improving the quality of life for for people around the world. From a performance standpoint, Q3 was a solid quarter.

I love the fact that two-thirds of Zimmer Biomed grew at upper single-digit or double-digit growth rates, delivering a bid on revenue, gross margin, EPS, and giving us the confidence to raise guidance for the rest of the year. We got work to
do in our USNE franchise, and we're doing ?it. I love the strong innovation cycle, which is about to get amplified with the launch of a monogram, uh pending approval of course.

And the transformation of the US go to market channel is going better than expected. So with roughly 50 days to close the year, we lag where we're
?at. We look forward to uh the next update in early 2027. Thank

Passages & reports (7)
  • Thank you. We uh started the uh the call this morning with gratitude. Uh, I want to close …
  • the world. From a performance standpoint, Q3 was a solid quarter. I love the fact that two…
  • do in our USNE franchise, and we're doing
  • it.
  • I love the strong innovation cycle, which is about to get amplified with the launch of a m…
  • at.
  • We look forward to uh the next update in early 2027. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

This concludes today's call. Thank you for your participation. You may now disconnect.

Passages & reports (1)
  • This concludes today's call. Thank you for your participation. You may now disconnect.
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 605. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T04:19:26.616Z.
Transcript version v1-71b9f2088a2826e7000d · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.